about
Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerDifferential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer ProgressionPrediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancerAndrogen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder CancerAssociation of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.Stat3 promotes metastatic progression of prostate cancer.Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.Does patient age affect survival after radical cystectomy?PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay.Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy.Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy.Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre.Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer.Regulation of prostate cell collagen receptors by malignant transformation.Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.Repeat multiparametric MRI in prostate cancer patients on active surveillance.Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.New prostate cancer grade grouping system predicts survival after radical prostatectomy.Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasionMetformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activityClonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cellsIncreased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy
P50
Q27853341-3A8E7436-F494-4E0C-BBF9-DB9674004678Q28480861-0ED3607F-BB6B-4B0C-B1E9-3B03E3FD0F82Q28550287-778B8276-5AB9-41F4-8888-CAC02226B83DQ30490354-BADA9BD9-4E63-479B-A632-7A3D87037FEFQ34216102-68BB36EA-EBD1-4061-BF7F-4D8CCC9291F7Q35380142-673F7FDD-3DFE-4D51-BA7F-499E6F873AA5Q35685196-006A96D5-7A13-42D6-B05C-D307E2A1BA65Q35703471-3895B027-683B-4F9A-A772-889066955CBDQ35995721-A23FDD11-7BAE-4905-89F4-56881EA297FEQ36691140-AF281730-EB86-4760-AEEB-284896FE9007Q37386391-2487CCDE-07BC-4AEC-A648-BEB987E0F40DQ38007021-EE52A89E-17C5-4332-ACF6-52B017212A8AQ38654992-3CDEFD8F-ADD1-40DD-8A8E-DEEE4A5F86C2Q39020147-7A00F804-900D-4E82-BF14-B37BB550A2D0Q39653761-040E8809-F6FF-4254-AFBA-4B6F871662DDQ39675961-2117A824-CB66-4ADA-A3BE-9EE6A8B775C1Q40011557-CA000DED-6953-421E-8479-C92F73C8E914Q40591422-09EF5731-E2F1-4FF8-9E1A-4A378CA0076DQ42237188-B7990C9B-04F6-45B1-9CAE-125A2EC20C82Q42436019-89E1C1FA-793D-4C7A-949A-EABFE2E5F2BDQ42492952-5CB7AE28-87C0-4A5C-B9DA-BD08469EB3D1Q44544470-D6F93981-A23A-49E8-AA0F-167B7A8DABE9Q45948761-7B1D652D-60E2-4AD4-B4D1-2B1466526A96Q46384526-3549A982-8F4F-4441-A765-8EEC69FEFEA1Q46694332-BC4BFB33-9706-4814-870B-EE4A23D4FDC9Q47103101-54C863F1-AF72-4834-B3FE-9F1DDD9E9CD3Q47759609-287D0733-408D-449B-BC61-08F52A065519Q47847847-1C10D775-3CDE-455F-A951-AA5F485A31B9Q48103088-24456188-5B18-49D7-A911-B3AAF280CE3EQ48342579-D97A4641-6EFF-442C-81AD-61AB04A9D38EQ49562114-74DB8126-E2C5-46AF-8E97-318F78C43AE6Q49971107-5AC61D89-02A0-43FB-8EAC-FC04031C0C40Q50967045-B275494F-953C-4EB6-B67D-BA5E87F075FBQ51549809-2118BB59-E163-48D3-A692-D44523A6F441Q51785008-8AD53891-1AA3-4527-9D80-36390D490ADBQ54686436-BFC33334-7E92-4F06-A82D-61D6C59F5E55Q57274753-2C924270-98EC-4E88-8BC3-9C203C8D80A4Q57462715-F8BC3637-B672-47F4-8ECE-825AB22535ACQ63965963-959E401D-4793-4AEB-AFA6-4A74AC1E8AEFQ63966748-3B29BE5A-4C5E-41C9-A37F-0F6B88E945F0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tuomas Mirtti
@ast
Tuomas Mirtti
@en
Tuomas Mirtti
@es
Tuomas Mirtti
@nl
Tuomas Mirtti
@sl
type
label
Tuomas Mirtti
@ast
Tuomas Mirtti
@en
Tuomas Mirtti
@es
Tuomas Mirtti
@nl
Tuomas Mirtti
@sl
prefLabel
Tuomas Mirtti
@ast
Tuomas Mirtti
@en
Tuomas Mirtti
@es
Tuomas Mirtti
@nl
Tuomas Mirtti
@sl
P106
P31
P496
0000-0003-0455-9891